beneve glp-1 Support | Appetite support for cravings and fullness control GLP-ONE Support Gut Health Booster

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

Treatment Suitability** - The clinic reserves the right to refuse or reschedule treatments if the patient is deemed unsuitable based on medical assessment, contraindications, or other relevant factors

Always follow the specific storage instructions in your medication's patient information leaflet or SmPC

Para los laboratorios centrados en farmacologa peptdica oral, estas cpsulas eliminan el paso de reconstitucin y las preocupaciones de esterilidad inherentes al trabajo con polvos liofilizados

[Normal storage condition= Dry, well-ventilated place at 15-25C with no major temperature fluctuations] Precaution For external use only